Les antidépresseurs durant la grossesse : des ... - Profession Santé

De la mère au nourrissonRéférences1. Martin B, Saint-André M. Dépression et troublesanxieux. Dans: Ferreira E. Grossesse et allaitement:guide thérapeutique. Montréal : Éditions du CHUSainte-Justine, 2007:539-59.2. Pearlstein T. Perinatal depression: treatmentoptions and dilemmas. Rev Psychiatr Neurosci2008;33(4):302-18.3. Talge NM, Neal C, Glover V. Antenatal maternalstress and long-term effects on child neurodevelopment:how and why? Journal of child psychologyand psychiatry, and allied disciplines 2007;48(3-4):245-61.4. Ramos E, St-André M, Rey E et coll. Duration ofantidepressant use during pregnancy and risk ofmajor congenital malformations. Br J Psychiatry2008;192:344-50.5. O’Brien L, Einarson TR, Sarkar M et coll. Doesparoxetine cause cardiac malformations? J ObstetGynaecol Can 2008;30(8):696-701.6. Oberlander TF, Warburton W, Misri S et coll. Majorcongenital malformations following prenatal exposureto serotonin reuptake inhibitors and benzodiazepinesusing population-based health data. BirthDefects Res (Part B) 2008;83:68-76.7. Diav-Citrin O, Shechtman S, Weinbaum D et coll.Paroxetine and fluoxetine in pregnancy: a prospective,multicenter, controlled, observationalstudy. Br J Clin Pharmacol 2008;66(5):695-705.8. Berard A, Ramos E, Rey E et coll. First trimesterexposure to paroxetine and risk of cardiac malformationsin infants: the importance of dosage. BirthDefects Res B Dev Reprod Toxicol 2007;80(1):18-27.9. Hemels ME, Einarson A, Koren G et coll. Antidepressantuse during pregnancy and the rates of spontaneousabortions: a meta-analysis. Ann Pharmacother2005;39(5):803-9.10. Rahimi R, Nikfar S, AbdollahiM. Pregnancy outcomes following exposure to serotoninreuptake inhibitors: a meta-analysis of clinicaltrials. Reprod Toxicol 2006;22(4):571-5.11. Simon GE, Cunningham ML, Davis RL. Outcomesof prenatal antidepressant exposure. Am J Psychiatry2002;159(12):2055-61.12. Davis RL, Rubanowice D, McPhillips H et coll.Risks of congenital malformations and perinatalevents among infants exposed to antidepressantmedications during pregnancy. PharmacoepidemiolDrug Saf 2007;16(10):1086-94.13. Ferreira E, Carceller AM, Agogue C et coll. Effectsof selective serotonin reuptake inhibitors and venlafaxineduring pregnancy in term and pretermneonates. Pediatrics 2007;119(1):52-9.14. Chambers CD, Johnson KA, Dick LM et coll. Birthoutcomes in pregnant women taking fluoxetine. NEngl J Med 1996;335(14):1010-5.15. Källén B. Neonate characteristics after maternaluse of antidepressants in late pregnancy. ArchPediatr Adolesc Med 2004;158(4):312-6.16. Wen SW, Walker M. The use of selective serotoninreuptake inhibitors in pregnancy. J Obstet GynaecolCan 2004;26(9):819-22.17. Pastuszak A, Schick-Boschetto B, Zuber C et coll.Pregnancy outcome following first-trimester exposureto fluoxetine (Prozac). JAMA 1993;269(17):2246-8.18. Kulin NA, Pastuszak A, Sage SR et coll. Pregnancyoutcome following maternal use of the new selectiveserotonin reuptake inhibitors: a prospective controlledmulticenter study. JAMA 1998;279(8):609-10.19. Hendrick V, Smith LM, Suri R et coll. Birth outcomesafter prenatal exposure to antidepressant medication.Am J Obstet Gynecol 2003;188(3):812-5.20. Malm H, Klaukka T, Neuvonen PJ. Risks associatedwith selective serotonin reuptake inhibi torsin pregnancy. Obstet Gynecol 2005;106(6):1289-96.21. Moses-Kolko EL, Bogen D, Perel J et coll. Neonatalsigns after late in utero exposure to serotonin reuptakeinhibitors: literature review and implications for clinicalapplications. JAMA 2005;293(19):2372-83.22. Boucher N, Beaulac-Baillargeon L. A new look atthe neonate‘s clinical presentation after in uteroexposure to antidepressants in late pregnancy. JClin Psychopharmacol 2008;28:334-9.23. Källén B, Otterblad Olausson P. Maternal use ofselective serotonin re-uptake inhibitors and persistentpulmonary hypertension of the newborn.Pharmacoepidemiol Drug Saf 2008;17(8):801-6.24. Chambers CD, Hernandez-Diaz S, Van Marter LJet coll. Selective serotonin-reuptake inhibitors andrisk of persistent pulmonary hypertension of thenewborn. N Engl J Med 2006;354(6):579-87.25. Andrade SE, McPhillips H, Loren D et coll. Antidepressantmedication use and risk of persistentpulmonary hypertension of the newborn. PharmacoepidemiolDrug Saf 2009;18:246-52.26. Gentile S. SSRIs in pregnancy and lactation: emphasison neurodevelopmental outcome. CNS Drugs2005;19(7):623-33.27. Cohen LS, Altshuler LL, Harlow BL et coll. Relapseof major depression during pregnancy in womenwho maintain or discontinue antidepressant treatment.JAMA 2006;295(5):499-507.28. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancyand lactation. A reference guide to fetal andneonatal risk. 8 e éd. Philadelphie: William Wilkins;2008.29. Altshuler LL, Cohen L, Szuba MP et coll. Pharmacologicmanagement of psychiatric illness duringpregnancy: dilemmas and guidelines. Am J Psychiatry1996;153(5):592-606.30. McElhatton PR, Garbis HM, Elefant E et coll. Theoutcome of pregnancy in 689 women exposed totherapeutic doses of antidepressants. A collaborativestudy of the European Network of TeratologyInformation Services (ENTIS). Reprod Toxicol1996;10(4):285-94.31. Nulman I, Rovet J, Stewart DE et coll. Childdevelopment following exposure to tricyclic antidepressantsor fluoxetine throughout fetal life: aprospective, controlled study. Am J Psychiatry2002;159(11):1889-95.32. Wen SW, Walker M. Risk of fetal exposure to tricyclicantidepressants. J Obstet Gynaecol Can2004;26(10):887-92.33. Källén B, Otterblad Olausson P. Antidepressantdrugs during pregnancy and infant congenital heartdefect. Reprod Toxicol 2006;21(3):221-2.34. GlaxoSmithKline. EPIP083: Updated PreliminaryReport on Bupropion and Other Antidepressants,including Paroxetine, in Pregnancy and the Occurrenceof Cardiovascular and Major Congenital Malformation,2005. [En ligne. Consulté le 18 mars2006.]; http://ctr.gsk.co.uk/Summary/paroxetine/studylist.asp.35. Goldstein DJ, Corbin LA, Sundell KL. Effects offirst-trimester fluoxetine exposure on the newborn.Obstet Gynecol 1997;89(5 Pt 1):713-8.36. Wogelius P, Norgaard M, Gislum M et coll. Maternaluse of selective serotonin reuptake inhibitorsand risk of congenital malformations. Epidemiology2006;17(6):701-4.37. Källén BA, Otterblad Olausson P. Maternal use ofselective serotonin re-uptake inhibitors in early pregnancyand infant congenital malformations. BirthDefects Res A Clin Mol Teratol 2007;79(4):301-8.38. Sivojelezova A, Shuhaiber S, Sarkissian L et coll.Citalopram use in pregnancy: prospective comparativeevaluation of pregnancy and fetal outcome.Am J Obstet Gynecol 2005;193(6):2004-9.39. Inman WH, Kubot K, Pearce G. PEM Report Number6. Paroxetine. Pharmacoepidemiol Drug Saf1993;2:393-422.40. Unfred CL, Chambers C, Felix R. Birth outcomesamong pregnant women taking paroxetine. OTIS14 th annual meeting (Organization of TeratologyInformation Services); Montréal, Qc.; 2001.41. Schloemp S, Paulus WE, Sterzik S, et coll. Congenitalmalformations after antidepressant medicationwith paroxetine in early pregnancy ? [Résumé]. HumReprod 2006;21(Suppl 1):i12.42. Cole JA, Ephross SA, Cosmatos IS et coll. Paroxetinein the first trimester and the prevalence ofcongenital malformations. PharmacoepidemiolDrug Saf 2007;16(10):1075-85.43. Einarson A, Pistelli A, DeSantis M, et coll. Evaluationof the risk of congential cardiovascular defectsassociated with use of paroxetine during pregnancy.Am J Psychiatry 2008;165(6):749-52.44. Bar-Oz B, Einarson T, Einarson A et coll. Paroxetineand congenital malformations: metaanalysisand consideration of potential confoundingfactors. Clin Ther 2007;29(5):918-26.45. Alwan S, Reefhuis J, Rasmussen SA et coll. Use ofselective serotonin-reuptake inhibitors in pregnancyand the risk of birth defects. N Engl J Med2007;356(26):2684-92.46. Louik C, Lin AE, Werler MM et coll. First-trimesteruse of selective serotonin-reuptake inhibitors andthe risk of birth defects. N Engl J Med2007;356(26):2675-83.47. Sanz EJ, De-las-Cuevas C, Kiuru A et coll. Selectiveserotonin reuptake inhibitors in pregnantwomen and neonatal withdrawal syndrome: adatabase analysis. Lancet 2005;365(9458):482-7.48. Cissoko H, Swortfiguer D, Giraudeau B et coll.Exposition aux antidépresseurs inhibiteurs de larecapture de la sérotonine (IRS) en fin de grossesse: retentissement néonatal. Arch Pediatr2005;12(7):1081-4.49. Cohen LS, Heller VL, Bailey JW et coll. Birth outcomesfollowing prenatal exposure to fluoxetine.Biol Psychiatry 2000;48(10):996-1000.50. Maschi S, Clavenna A, Campi R et coll. Neonataloutcome following pregnancy exposure to antidepressants:a prospective controlled cohort study.BJOG 2007 :283-9.51. Oberlander TF, Misri S, Fitzgerald CE et coll. Pharmacologicfactors associated with transient neonatalsymptoms following prenatal psychotropicmedication exposure. J Clin Psychiatry 2004;65(2):230-7.52. Gentile S. Serotonin reuptake inhibitor-induced perinatalcomplications. Paediatr Drugs 2007;9(2):97-106.53. Levinson-Castiel R, Merlob P, Linder N et coll. Neonatalabstinence syndrome after in utero exposure toselective serotonin reuptake inhibitors in term infants.Arch Pediatr Adolesc Med 2006;160(2):173-6.54. Casper RC, Fleisher BE, Lee-Ancajas JC et coll. Follow-upof children of depressed mothers exposedor not exposed to antidepressant drugs duringpregnancy. J Pediatr 2003;142(4):402-8.55. Einarson A, Fatoye B, Sarkar M et coll. Pregnancyoutcome following gestational exposure to venlafaxine:a multicenter prospective controlled study.Am J Psychiatry 2001;158(10):1728-30.56. Yaris F, Kadioglu M, Kesim M et coll. Newer antidepressantsin pregnancy: prospective outcome ofa case series. Reprod Toxicol 2004;19(2):235-8.57. Lennestal R, Källén B. Delivery outcome in relation tomaternal use of some recently introduced antidepressants.J Clin Psychopharmacol 2007;27(6):607-13.58. GlaxoSmithKline. The Bupropion Pregnancy Registry- Final report (1 September 1997 through 31 March2008); 2008.59. Chun-Fai-Chan B, Koren G, Fayez I et coll. Pregnancyoutcome of women exposed to bupropionduring pregnancy: a prospective comparative study.Am J Obstet Gynecol 2005;192(3):932-6.60. Cole JA, Modell JG, Haight BR et coll. Bupropion inpregnancy and the prevalence of congenital malformations.Pharmacoepidemiol Drug Saf 2007;16(5):474-84.61. Biswas PN, Wilton LV, Shakir SA. The pharmacovigilanceof mirtazapine: results of a prescription eventmonitoring study on 13554 patients in England. JPsychopharmacol 2003;17(1):121-6.62. Djulus J, Koren G, Einarson TR et coll. Exposure tomirtazapine during pregnancy: a prospective, comparativestudy of birth outcomes. J Clin Psychiatry2006;67(8):1280-4.63. Sokolover N, Merlob P, Klinger G. Neonatal recurrentprolonged hypothermia associated withmaternal mirtazapine treatment during pregnancy.Can J Clin Pharmacol 2008;15(2):e-188-e90.64. Einarson A, Bonari L, Voyer-Lavigne S et coll.A multicentre prospective controlled study todetermine the safety of trazodone and nefazodoneuse during pregnancy. Can J Psychiatry2003;48(2):106-10.20 Québec Pharmacie vol. 56 n° 5 septembre 2009